Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Akebia Therapeutics ( (AKBA) ) has provided an announcement.
On January 27, 2026, Akebia Therapeutics signed a new 84‑month lease for approximately 43,474 square feet of combined office and laboratory space at 180 CityPoint in Waltham, Massachusetts, positioning the company to relocate its corporate headquarters from Cambridge around September 2026 as its current lease nears expiration. The deal, which includes starting annual rents of about $898,317 for office space and $1,046,920 for lab space with scheduled annual increases, a security deposit via letter of credit, and obligations for taxes and operating expenses, underscores Akebia’s long-term commitment to its operational footprint and lab capacity in the Boston biotech corridor. On January 28, 2026, Akebia also amended and restated executive severance agreements for President and CEO John P. Butler and CFO Erik J. Ostrowski, enhancing cash severance, COBRA reimbursement, and equity-vesting protections in the event of termination without cause, resignation for good reason, or a change in control, moves that bring the company’s executive employment terms closer to prevailing market practice and are likely aimed at leadership retention and stability during potential strategic transitions.
The most recent analyst rating on (AKBA) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Akebia Therapeutics stock, see the AKBA Stock Forecast page.
Spark’s Take on AKBA Stock
According to Spark, TipRanks’ AI Analyst, AKBA is a Neutral.
The score is held back primarily by balance-sheet leverage and a still-fragile profitability track record, plus a clearly bearish technical trend. These are partially offset by improving TTM cash generation/operating performance and constructive earnings-call fundamentals around Vafseo uptake, with corporate updates adding both upside optionality and regulatory/strategy risk.
To see Spark’s full report on AKBA stock, click here.
More about Akebia Therapeutics
Akebia Therapeutics is a biopharmaceutical company focused on developing and commercializing therapies, including office and laboratory operations in Massachusetts that support its research and corporate functions in the life sciences sector.
Average Trading Volume: 3,753,579
Technical Sentiment Signal: Sell
Current Market Cap: $384.8M
For an in-depth examination of AKBA stock, go to TipRanks’ Overview page.